Related Experiment Video
Updated: Oct 3, 2025

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis
Published on: December 21, 2014
Filgrastim, fibrinolysis, and neovascularization
Darwin Eton1, Guolin Zhou2, Tong-Chuan He3
1Department of Surgery, University of Illinois Chicago, Chicago, Illinois, USA.
Filgrastim (a granulocyte colony stimulating factor) combined with a programmed compression pump (PCP) promotes artery recanalization in chronic limb-threatening ischemia (CLTI). This novel treatment induces fibrinolysis and a pro-angiogenic environment, warranting further clinical investigation.
Area of Science:
- Vascular Biology
- Regenerative Medicine
- Ischemia Research
Background:
- Chronic limb-threatening ischemia (CLTI) presents a significant challenge in vascular medicine.
- Current treatments for CLTI have limitations, necessitating novel therapeutic approaches.
- Understanding molecular mechanisms of neovascularization and fibrinolysis is crucial for improving CLTI outcomes.
Purpose of the Study:
- To investigate the effects of Filgrastim, a granulocyte colony stimulating factor, combined with a programmed compression pump (PCP) on segmental recanalization in CLTI patients.
- To explore the molecular evidence of fibrinolysis and neovascularization induced by this combined therapy.
- To assess the safety and efficacy of a novel Filgrastim dosimetry in CLTI.
Main Methods:
- A comparative study involving CLTI patients treated with PCP alone or with Filgrastim and PCP.
- Plasma and serum samples were analyzed using Enzyme-Linked Immunosorbent Assay (ELISA) to measure plasmin, fibrin degradation products (FDP), and pro-angiogenic proteins (HGF, MMP-9, VEGF A).
- Blood draws were conducted at baseline and at specific time points following Filgrastim administration and PCP treatment.
Main Results:
- Filgrastim administration, independent of PCP, significantly increased plasma concentrations of plasmin (>10-fold) and FDP (>5-fold) after the 5th and 10th doses.
- Significant increases in pro-angiogenic proteins, including HGF, MMP-9, and VEGF A, were observed.
- The combined therapy demonstrated fibrinolysis and induced a pro-angiogenic milieu without causing acute hemorrhage.
Conclusions:
- Filgrastim at a novel dosimetry, in conjunction with PCP, effectively induces fibrinolysis and promotes a pro-angiogenic environment in CLTI patients.
- This therapeutic strategy shows potential for promoting neovascularization and artery recanalization in chronically ischemic tissues.
- Further clinical trials are warranted to validate this approach in CLTI and other ischemic conditions.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

